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ABSTRACT 
 
Background. Renal insufficiency is increasingly common in end-stage liver disease and allocation 
of livers to this category of patient has escalated. The frequency of combined liver-kidney 
transplantation (CLKT) has consequently increased. Indications for CLKT in children differ from 
those for adults and typically include rare congenital conditions; subsequently limited numbers of 
this procedure have been performed in paediatric patients worldwide. Scant literature exists on the 
subject.  
Methods. Subsequent to institutional approval, a retrospective chart analysis of all paediatric 
CLKTs performed at the Transplant Unit, Wits Donald Gordon Medical Centre, University of the 
Witwatersrand, Johannesburg, South Africa between January 2005 and July 2013 was conducted.  
Results. Defining children as younger than 18 years of age, 43 patients had received a liver 
transplant since 2005, of whom 8 received a CLKT. Indications included autosomal recessive 
polycystic kidney disease (n=3), primary hyperoxaluria type 1 (n=4) and heterozygous factor H 
deficiency with atypical haemolytic uraemic syndrome (n=1). Graft combinations included whole 
liver and one kidney (n=5), whole liver and two kidneys (n=1) and left lateral liver segment and one 
kidney (n=2), all from deceased donors. Patient age ranged from 4 to 17 years (median 9) and 
included 4 females and 4 males. Weight ranged from 13 to 42 kg (median 22.5). We describe one 
in-hospital mortality. The remaining 7 patients were long-term survivors with a survival range from 
6 to 65 months.  
Conclusions. Although rarely indicated in children, CLKT is an effective treatment option, 
appropriately utilising a scarce resource and significantly improving quality of life in the recipient. 
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Combined Paediatric Liver-Kidney Transplantation:  
Analysis of our experience 
 
 
INTRODUCTION 
 
The Wits Donald Gordon paediatric liver transplant program was established in November 2005 
and is one of two such units in Sub-Saharan Africa. It forms part of the solid organ transplant unit 
run by the Wits Donald Gordon Medical Centre (WDGMC) Transplant Division, a public-private 
partnership catering to an ever-increasing patient population. The program has performed 42 
paediatric liver transplants to date. Of these 8 were combined liver-kidney transplants, the first of 
which was performed on the 18th August 2007. 
 
Since the first successful kidney and liver transplants in the 1950s and 1960s respectively, both 
patient and graft survival have improved dramatically (1). The first successful combined liver-
kidney transplant (CLKT) was subsequently performed by Margreiter in Austria in 1984 (2). Both 
the liver and kidney were transplanted from a single deceased donor into a 28 year-old recipient 
who had liver failure as a result of chronic hepatitis B infection, as well as end stage renal 
dysfunction. One month following transplant both kidney and liver function had normalised, the 
patient had returned to a premorbid level of functioning, and the procedure was deemed a success. 
Renal insufficiency, secondary to a variety of causes, is a common problem in patients suffering 
from end-stage liver disease, particularly in adults (3). Renal impairment in liver transplant patients 
amplifies the risk for both postoperative chronic kidney disease (CKD) and procedure-related 
mortality. With the introduction of the model of end-stage liver disease (MELD) score for liver 
transplantation the allocation of organs to patients with renal insufficiency has increased (1,2,4). 
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Consequently, the number of CLKT in adults has shown a considerable increase over the last few 
years.  
 
In children on the other hand, the most common causes for CLKT are congenital diseases affecting 
both liver and kidney, such as primary hyperoxaluria type 1 (PH-1) and autosomal recessive 
polycystic kidney disease (ARPKD), amongst others (2). These diseases have a low incidence and, 
as a result, CLKT in children is still a therapy performed in a very limited number of cases. Little 
data is available in the literature regarding paediatric CLKT (1). 
Methods 
 
All paediatric patients undergoing CLKT at the WDGMC were identified from a prospective 
database. Overall 8 CLKT’s were performed in 8 children between 2007 and the present. In the 
same time period 34 isolated liver transplants and 49 isolated kidney transplants (25 cadaver 
kidneys and 24 related living donor kidneys) were performed in children. 
 
The patients were analysed for recipient characteristics as listed in table 1, and the technical details 
of each procedure were noted. Pertinent intra and postoperative events were documented as were 
any postoperative complications, particularly those related to vascular, biliary or urinary 
reconstruction, and graft and patient survival were analysed. Finally, a retrospective English 
language Pubmed search was conducted from January 2013, looking for all published papers 
discussing CLKT. 
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Results 
 
Since 2007, 8 combined liver-kidney transplants have been performed and all are included in this 
retrospective review. None of the children had received previous transplants. The indications for 
CLKT were congenital hepatic fibrosis associated with polycystic kidney disease (n = 3), primary 
hyperoxaluria type 1 (n = 4) and heterozygous factor H deficiency with atypical haemolytic uraemic 
syndrome (n =1). The age of the patients ranged from 4 to 17 years (median = 9 years) and included 
4 females and 4 males. Their weight ranged from 13 to 42 kg (median = 22.5 kg). Patient waiting 
times since listing on the active transplant list ranged from 49 to 1383 days (median = 270 days). 
 
The specific surgical techniques for organ procurement, graft preparation and the respective implant 
procedures are well described, and only when techniques deviate from an accepted standard will 
they be discussed. Of note is that where recipient weight was less than 20 kilograms, there was a 
low threshold to establish arterial inflow to the donor kidney directly off the aorta, below the origin 
of the inferior mesenteric artery. Graft combinations were as follows: whole liver and one kidney (n 
= 5), whole liver and two kidneys (n = 1) and left lateral segment of liver and one kidney (n = 2). 
Median anaesthetic time was 7 hours and blood loss ranged from 80 ml to 4970 (median = 1831 
ml). 
Median blood volume transfused was 900 ml of leukocyte-depleted packed red blood cells and 
other blood products, and 450ml of cell saved whole blood. Blood group crossmatch was identical 
in 7 and compatible in 1.  
 
Induction immunosuppresion consisted of Daclizumab (Zenepax) and Solumedrol, with dosages 
adjusted for weight. Postoperative maintenance immunosuppression consisted of mycophenolate 
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mofetil (CellCept), tacrolimus (Prograf) and prednisone. In one case Everolimus was used. With 
respect to pre-operative dialysis, 6 patients received haemodialysis, 1 peritoneal dialysis, and 1 
patient was transplanted preemptively. All patients with hyperoxalurea received 3 months of post-
operative haemodialysis to clear residual systemic oxalic acid. One patient underwent sequential 
nephrectomies, the first pre- and the second post CLKT, both for severe nephrocalcinosis and 
recurrent urinary tract infections (UTI’s), whilst a 2nd patient had bilateral nephrectomies for 
recurrent atypical UTIs post transplant. Native kidneys in the remaining patients remained 
asymptomatic and were left in situ. 
 
There was 1 mortality in this series. The remaining 7 patients are dialysis free, with excellent 
quality of life subjectively, with a mean follow up of 2,17 years. The mortality was related to 
surgical complications of hepatic artery and portal vein thrombosis peri-operatively. Although the 
patient was re-listed, a second liver did not become available and the patient died of acute hepatic 
failure. In the patient who received the two kidneys as an en bloc graft, one kidney infarcted 
secondary to renal artery thrombosis, although this had no impact on renal function. A further 
patient developed a wound haematoma which resolved with conservative management. The last 
patient, who received a reduced left lateral segment graft and single kidney, developed an 
abdominal compartment syndrome which required urgent decompression and closure with a large 
mesh. 
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Technical details of the CLKT 
 
The purpose of this description of the technical aspects of CLKT is not to repeat the basic steps of 
the operation that have been published extensively and remain the gold standard, but rather to 
highlight where we have deviated from, or modified, the standard procedure and give an 
explanation as to why we did so. 
 
Our liver transplant technique was routine. All donor kidneys were placed extraperitoneally via a 
right-sided Rutherford-Morrison incision. We did not encounter the theoretical risk of skin bridge 
necrosis at the lateral aspects of the right subcostal and Rutherford-Morrison incisions where the 
two approximate. The right-sided extraperitoneal approach allows excellent access to the relevant 
vasculature, particularly the distal aorta and inferior vena cava, which may be required to establish 
adequate arterial inflow and venous outflow respectively. This is especially important when a large 
donor kidney is implanted into a small child, when up to 25-30% of the circulating blood volume is 
taken up by the transplanted kidney on release of clamps. Inadequate arterial inflow will 
compromise perfusion, causing subsequent necrosis of the graft. 
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DISCUSSION AND LITERATURE REVIEW 
 
The relative infrequency of CLKT in children is as a result of limited indications, which are rare 
conditions with low incidences that have not changed over the years (2). This leaves a challenging 
problem in determining the optimal indications for CLKT. In our patient cohort the indications for 
CLKT are listed in Table 1. According to the UNOS database, only 231 CLKT’s were performed in 
children from 1988 to date, these in 41 transplant centres (5). The median number of transplants per 
centre was 3 (average = 6). It is evident, even with the small numbers that we are reporting on, that 
our indications and numbers mirror those of the world literature. We will discuss the three most 
common indications for CLKT, namely primary hyperoxaluria type 1 (PH1), autosomal recessive 
polycystic kidney disease with congenital hepatic fibrosis, and heterozygous factor H deficiency 
with atypical haemolytic uraemic syndrome. 
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Table 1. Indications for combined liver-kidney transplantation in children 
Our cohort Literature 
Primary hyperoxaluria 
type 1 
4 Primary hyperoxaluria 
type 1 
49 
Polycystic kidney 
disease 
3 Polycystic kidney 
disease/ congenital 
hepatic fibrosis 
17 
Heterozygous factor H 
deficiency with atypical 
haemolytic uraemic 
syndrome 
1 Factor H deficiency 7 
  Methylmalonic 
acidaemia 
7 
  Alpha-1-antitrypsin 
deficiency 
4 
  Cyclosporin toxicity 2 
  Failed prior liver 
transplant 
2 
  Cystinosis 1 
  Drug toxicity 1 
  Glycogen storage 
disease 1a 
1 
  Autoimmune hepatitis/ 
hepatorenal syndrome 
1 
  Sclerosing cholangitis/ 
interstitial nephritis 
1 
  Biliary atresia 1 
  Liver disease secondary 
to parenteral nutrition 
1 
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Table 2. Reported combined liver-kidney transplants in children 
Author (Reference) 
Number 
CLKT Indication 
Mean age at 
transplant 
(years) 
Patient 
survival 
% 
Death censored 
renal allograft 
survival % 
% of patients 
with kidney 
rejection 
% of patients 
with liver 
rejection Morbidity/ Mortality 
Polinsky et al. 1 PH1 7.5 0 Not reported Not reported Not reported Early postoperative death (cause 
not specified) 
van ‘t Hoff et al. 1 MMA 13.5 100 100 0 0  
Grewel et al. 12 PKD/CHF (5) 
alpha-1-antitrypsin 
deficiency (2) 
Failed prior liver/ 
cyclosporin toxicity 
(2) 
Other (3) 
9.5 67 100 (4.8 yr) 42 42 4 deaths due to sepsis post 
transplant 
Ellis et al. 4 PH1 7.3 75 100 33 0 1 death post transplant (cause not 
specified) 
Shapiro et al. 9 PH1 8.5 78 100 (2.5 yr) Not reported Not reported 1 death due to sepsis/ 1 death due 
to PTLD 
Rogers et al. 8 PH1 (3) 
PKD/CHF (3) 
Cystinosis (1) 
Drug Toxicity (1) 
10.9 75 50 25 13 1 death due to pneumonia/ 1 
death due to PTLD 
Gagnadoux et al. 8 PH1 16.4 75 100 (5 yr) 12.5 12.5 2 deaths during transplant not 
specified 
Loreno et al. 1 alpha-1-antitrypsin 
deficiency 
15 100 100 0 100  
Remuzzi et al. 1 Factor H deficiency 2 100 100 Not reported 100 Re-transplanted liver at 1 month 
Millan et al. 6 PH1 1.2 100 100 (6.4 yr) 16.70 67  
Nagarajan et al. 2 MMA 15.5 100 100 Not reported Not reported  
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Table 2 continued. Reported combined liver-kidney transplants in children 
Author (Reference) 
Number 
CLKT Indication 
Mean age at 
transplant 
(years) 
Patient 
survival % 
Death 
censored renal 
allograft 
survival % 
% of 
patients 
with kidney 
rejection 
% of patients 
with liver 
rejection Morbidity/ Mortality 
Remuzzi et al. 1 Factor H deficiency 3 0 Not reported Not reported Not reported Split liver - intraop hypotension, 
early postoperative death 
Saland et al. 1 Factor H deficiency 5.5 100 100 0 100  
Kasahara et al. 5 MMA 15.1 100 Not reported Not reported Not reported  
Belingheri et al. 1 Glycogen storage 
disease 1a 
19 100 100 0 0  
Zanus et al. 4 PH1 (3) 
alpha-1-antitrypsin 
deficiency 
6 50 25 Not reported Not reported 2 deaths early post operative 
period (cause not specified)/ 1 
renal allograft loss 
Jalanko et al. 2 Factor H deficiency 9.5 100 100 0 50  
De La Cerda 10 PH1 (5) 
Autoimmune 
hepatitis/ 
hepatorenal 
syndrome (1) 
Sclerosing 
cholangitis/ 
interstitial nephritis 
(1) 
Biliary atresia/CsA 
toxicity (1) 
Liver disease 
secondary to 
parentreral 
nutrition/CKD 
unknown etiology 
(1) 
10 100 90 10 0 1 acute allograft rejection due to 
patient non compliance with 
medication 
Chava et al. 4 Not specified       
Mehrabi et al. 4 PH1 (3)  
PKD/CHF (1) 
8.8 Not reported Not reported Not reported Not reported  
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Table 2 continued. Reported combined liver-kidney transplants in children 
Author (Reference) 
Numbe
r CLKT Indication 
Mean age at 
transplant 
(years) 
Patient 
survival % 
Death censored 
renal allograft 
survival % 
% of patients 
with kidney 
rejection 
% of patients 
with liver 
rejection Morbidity/ Mortality 
Herden et al. 14 PH1 (7) 
PKD/CHF (7) 
8 100 93 Not reported Not reported Primary non function of the liver 
graft and impaired kidney 
function requiring re-CLKT (x2 
livers) 
One re-liver transplant for 
outflow problem with toxic liver 
damage 
Khan et al. 1 Factor H deficiency 3 100 100 100 100 Delayed renal graft function 
Sakamoto et al. 1 Caroli’s 
disease/ARPKD 
4.3 0 Not reported Not reported Not reported One death 
CLKT, combined liver-kidney transplantation; PH1, primary hyperoxaluria type 1; PKD, polycystic kidney disease; CHF, congenital hepatic fibrosis; MMA, methylmalonic 
acidemia; PTLD, post-transplant lymphoproliferative disorder 
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PH1 is an autosomal recessive metabolic condition caused by a congenital deficiency of alanine-
glyoxylate aminotransferase (AGT), a hepatic peroxisomal enzyme. Patients with this deficiency 
metabolise glyoxylate to oxalate and glycolic acid, instead of to glycine (6). The kidneys are 
subsequently burdened with eliminating the large oxalate load, which results in deposition of 
calcium-oxalate crystals in the kidney and progression to chronic renal failure. The condition is 
often more severe in infants, with end stage renal disease (ESRD) presenting before two years of 
age. By 15 years of age 50% of patients will have developed ESRD (1-3,7). As the glomerular 
filtration rate drops, oxalate is deposited systemically into bone and soft tissues including the retina, 
blood vessels, nerves and heart (6). If the condition is diagnosed early, and before significant renal 
failure is established, isolated liver transplantation (iLT) is an acceptable option, with excellent 
survival (7). However this only addresses the issue of oxalate formation, and it does not resolve the 
problem of an already high burden of oxalate which would force the kidneys to eliminate the 
remaining stores. This can contribute to progressive chronic kidney disease requiring a renal 
transplant at a later stage.  
 
The converse is however not acceptable – graft survival after isolated kidney transplantation (iKT) 
for PH1 approximates 18 percent at 3 years, based on data from the European Dialysis and 
Transplant Association registry (8). This obviously occurs due to progressive nephrocalcinosis and 
urolithiasis and early graft failure, as hepatic AGT is still deficient, and oxalate over production 
continues. 
 
CLKT addresses both the primary metabolic insult, namely hepatic AGT deficiency, and the 
consequent end organ damage secondary to oxalosis, that being chronic renal failure. Reported 
outcomes have been varied however. Again the largest series of patients is from the European PH1  
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Transplant Registry. 127 transplants were performed in 117 patients between 1984 and 2005, 99 
CLKTs, 22 iLTs, and 6 patients underwent iLT followed by iKT. 10 year survival was 69% for all 
groups (9). Factors which were clearly shown to affect outcome and improve survival were the 
overall clinical condition of the patient at the time of transplantation, earlier diagnosis, and 
aggressive pretransplantation dialysis (1,2,4,9). 
 
Of interest is that despite a new liver, more than 50% of renal graft failures following CLKT were 
due to oxalate deposition in the new kidney, and that hyperoxaluria was detectable up to 45 months 
post transplantation. This oxalate burden should not be underestimated (2,10). Our current protocol 
is to dialyse all our PH1 cases for 3 months post transplantation, to decrease the oxalate stores and 
to mitigate any damage they might cause to the renal allograft by nephrocalcinosis or urolithiasis. 
Consideration should also be given to the shortage of deceased donor organs, and the pressure that 
this applies to other patients on the waiting list. Thus alternatives that should be considered once the 
decision to list has been taken include the feasibility of Related Living kidney donation as and when 
a Deceased Donor liver becomes available, as well as consideration of both Related Living kidney 
and liver transplantation simultaneously (1,11). 
 
Autosomal recessive polycystic kidney disease (PKD) is a disease with an incidence of 1 in 20 000 
live births and demonstrates a variable clinical progression (2,12). The most severely affected 
children present with ESRD either in the perinatal period or during early infancy. Liver 
involvement is a result of congenital hepatic fibrosis or Caroli disease, which may progress to portal 
hypertension, hypersplenism, thrombocytopaenia, and recurrent ascending cholangitis (Caroli 
syndrome) (6,13). As the liver disease is chronic and may not necessarily progress to failure, 
isolated kidney transplantation has been the standard intervention for ESRD secondary to PKD with 
minimal liver disease. Reported data on isolated kidney transplantation shows patient survival to be 
89% and death censored graft survival at 100% at 5 years (14). However Khan et al reported on 14 
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patients who had received isolated kidney transplantation in the presence of hepatic disease; 4 of the 
5 deaths in this series were due to complications from hepatic disease and 56% of the remaining 
survivors had complications related to congenital hepatic fibrosis at a mean of 6.3 years post 
transplantation (15). Davis et al published another retrospective study of 203 patients who received 
isolated kidney transplantation for similar indications (13). What is of particular interest in this 
study is the percentage of sepsis related deaths, 64%. Whilst sepsis is acknowledged as a common 
cause of death among the paediatric group of kidney transplant recipients, the North American 
Paediatric Renal Trials and Collaborative Studies registry report this at 28.9% (6,16). Although not 
proven, this may hypothetically suggest an increased rate of cholangitis related to congenital 
hepatic fibrosis, and the fact that these patients already have a heavily colonized biliary tree. This 
situation is possibly accentuated by subsequent immunosuppression (7,13). 
  
Whilst liver disease is always present in these patients, it does not always warrant transplantation, 
and isolated kidney transplant is often all that is required. When there is liver disease causing 
progressive and severe complications, CLKT is advocated. Although limited, outcome data 
following CLKT is favourable in both the adult and paediatric literature. CLKT should be 
considered when ESRD (as a result of ARPKD) and severe congenital hepatic fibrosis or hepatic 
failure are present. On occasion, liver disease secondary to the congenital hepatic fibrosis dominates 
the clinical picture, however we are not aware of any cases reported in the literature of isolated liver 
transplantation, and currently CLKT is recommended in this scenario (8,11).  
 
Heterozygous factor H deficiency with atypical haemolytic uraemic syndrome (HUS) is a very 
unusual indication for CLKT, with only 7 cases described in the literature to date. Factor H is 
produced in the liver and regulates the activation of the complement cascade via the alternative 
pathway. Qualitative or quantitative deficiencies in Factor H can result in the uninhibited deposition 
of complement, destruction of microvasculature and the phenotype of HUS. There are more than 60 
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heterozygous factor H mutations which are responsible for approximately 30% of recurrent cases of 
HUS. They carry a poor prognosis, resulting in ESRD or death in 50% of patients (3,9,17,18). 
Outcomes following isolated kidney transplantation are equally poor with recurrences in the range 
of 50 to 100% (3,17). CLKT addresses both the qualitative and quantitative factor H issues and 
restores renal function.  
Recently Eculizimab has been registered for the management of aHUS and the recommendation is 
to do a kidney transplant combined with lifelong Eculizimab therapy (19). Unfortunately the 
lifelong cost of this drug is currently prohibitively high. The alternative is  CLKT which is a more 
aggressive treatment option and is associated with greater morbidity and mortality due to the 
combined organ transplant. In order to reduce this risk an option is to use Eculizimab peri-
operatively in CLKTs in order to reduce the complications related to uninhibited complement 
activation. Where anti-factor H antibodies exist then a CKLT may need to be combined with 
lifelong plasma exchange and therapy aimed at reducing antibody levels. Our patient did not have 
anti-factor H antibodies. 
 
At the time of writing, CLKT has been reported in seven patients (including our own case) with 
factor H-associated HUS. Most recently Khan et al reported on one case which was uncomplicated,  
apart from a short period of delayed renal graft function of the kidney. Saland et al also published a 
single case with 100% dual graft survival at 2 years (3). Our case was equally uncomplicated, with 
dual graft survival more than 2 years post transplant. Plasma exchange has been suggested in the 
immediate pretransplant period, or intraoperatively, as it restores normal factor H function and 
inhibits unregulated complement deposition until the new liver has had time to normalise factor H 
levels and function. Also, because split liver grafts are more susceptible to poor perfusion and the 
resultant increased complement activation, it is suggested by some units that whole liver grafts be 
used (18). It should be stated that this is not the practice of our unit, and we would consider the use 
of split grafts without reservation. 
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Thus although there are only a limited number of documented cases in addition to our own single 
case experience, it has been demonstrated that in light of these recent successes as well as the poor 
outcomes of alternative therapy, CLKT should be considered for this subgroup of patients.  
 
All published CLKTs (including adults) extracted from the PubMed database are shown in Table 2. 
From 1984 to present, 3568 cases have been reported. A significantly smaller number, 108 cases, 
have been performed in children, including our series. The majority of transplants were for primary 
hyperoxaluria type 1 (n = 52, 48.6%), autosomal recessive polycystic kidney disease                      
(n = 20, 18.5%) and atypical Factor H deficiency  (n = 8, 7.4%). Immunosuppression varied 
significantly from tacrolimus or cyclosporin A monotherapy, to multiple drug combinations and 
even quadruple therapy with antithymoglobulin, cyclosporin A, methylprednisolone and 
azathioprine. When reported, complications were predominantly sepsis related (n = 7, 6.5%), and 
invariably resulted in mortality.  
 
Since CLKT’s are now more commonly performed, there has been debate as to whether the liver 
allograft offers “immunoprotection” to the kidney allograft. In 2003, a review of the UNOS 
database illustrated a lower six-month cumulative acute renal rejection rate for patients receiving 
CLKT as opposed to isolated kidney transplantation (21.5 versus 30.1%). When reviewing single 
centre experiences the results appear even more promising, however the small numbers reported in 
these studies should caution their interpretation. Grewel et al reported a 42% acute renal allograft 
rejection rate however only two of the five cases were proven by biopsy (20). Rogers et al showed a 
25% acute renal allograft rejection rate versus 86% rejection rate in their kidney after liver 
transplant cohort (21). More recently De La Cerda et al conducted a single center retrospective 
case-control study which looked at 10 children who had CLKT and survived to 6 months, 
comparing them to a control group of 20 kidney only transplants matched for age, era and 
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immunosuppression (22). In the CLKT group only 1 acute renal allograft rejection was reported at 7 
years secondary to non-compliance of medication. In the same period the kidney only group had 16 
acute rejection episodes. There was also no hepatic rejection in the CLKT. The study was, however, 
too small to uncover a significant difference in immunologically mediated kidney allograft failure. 
The same authors therefore looked at UNOS paediatric data - they analysed 111 CLKT and 3798 
kidney-only transplants between 1995 and 2005. What they found is that although renal graft loss in 
the first 6 months was higher in the CLKT (20.1% vs 5.9%), death censored kidney allograft 
survival at 5 years was significantly better in the CLKT group and that function did not continue to 
deteriorate as it did in the kidney only group (22). 
 
When reviewing the literature there are a few reported cases where patients required re-liver 
transplant after CLKT for graft non-function or rejection. In one case a patient received two  
subsequent liver transplants following the initial CLKT (23). Although that patient did not 
ultimately survive, the feasibility of subsequent transplantation does exist, obviously dependant on 
the availability of organs. This does raise the question as to whether our patient could have survived 
had the resource been available, at the same time raising the question of utilizing a scarce resource. 
Conclusion 
 
In the paediatric age group, the most common indication for CLKT are metabolic diseases which 
affect either the kidney alone with or without liver disfunction, or congenital abnormalities 
affecting both organs simultaneously. CLKT has good results in select groups of patients and long 
term survival approaches that of liver transplantation alone. What lends itself to more favourable 
results, is when patients are evaluated early and listed before they become severely ill or manefest 
systemic complications. In patients with PH1, nephrocalcinosis and systemic oxalosis can become a 
problem. All patients in our series were dialysed for 3 months post operatively to clear systemic 
  23 
oxalic acid. The literature presents two conflicting views; some studies show good results following 
CLKT while others report poorer results. Irreversible renal dysfunction should not exclude children 
with severe liver disease from consideration for liver transplantation if it is performed with a 
simultaneous kidney transplant. Factors that negatively affect the outcome of isolated liver 
transplantation (UNOS status and re-transplantation) must be considered in determining the 
suitability of any given candidate for CLKT but ultimately ESRD and poor quality of life need to be 
offset against the potential excellent long-term benefits of a timeous CLKT. Similarly our patients 
with ARPKD showed excellent graft and patient survival. 64-80% of mortality occuring in ARPKD 
can be attributed to to cholangitis or sepsis which is related to their liver disease. As surgical 
mortality in paediatric liver transplant recipients has been shown to be < 10% at one year, it is a 
viable option in patients with recurrent cholangitis or complications of portal hypertension, to do a 
CLKT to decrease overall mortality. There is suggestive clinical evidence that CLKT offers a 
degree of immunologic protection to the renal allograft. 
 
Our centre demonstrated an excellent survival rate, with satisfactory results in terms of mortality 
and morbidity in comparision to reported data in worldwide literature. 
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